{
    "data": [
        {
            "id": "690505a0ecb8a7000146325d",
            "title": "Apple Breaks Records In Q4, Tim Cook Says Q1 Will Be Even Better: &#39;The Best Ever For The Company&#39;",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Apple Inc</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/AAPL\" target=\"_blank\">AAPL</a>) stock hit new all-time highs after the company beat analyst estimates for revenue and earnings per share in<a href=\"https://www.benzinga.com/markets/earnings/25/10/48545962/apple-stock-hits-all-time-high-following-q4-earnings-beat-active-installed-base-reaches-record-levels-across-all-products\" target=\"_blank\"> the fourth quarter.</a> While the quarterly results set several company records, CEO <strong>Tim Cook</strong> said more records are coming in the next fiscal quarter.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li>AAPL is performing well relative to peers. <a href=\"https://www.benzinga.com/quote/AAPL\" rel=\"noreferrer noopener\" target=\"_blank\">Get the scoop here.</a></li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Apple Records To Fall In First Quarter</h2><!--/$--><!--$--><p class=\"block core-block\">Strong <a href=\"https://www.benzinga.com/topic/iphone-17\" target=\"_blank\">iPhone 17 sales</a> helped Apple beat analyst estimates in the fourth quarter, despite limited initial demand for the new smartphone factoring into the results, given the launch date of Sept. 19.</p><!--/$--><!--$--><p class=\"block core-block\">Cook highlighted the strength of the quarter during the <a href=\"https://www.youtube.com/watch?v=j2se-TYG3hw\" target=\"_blank\">company's conference call,</a> while also guiding for the first quarter to set several new company records.</p><!--/$--><!--$--><div class=\"sc-SfCGz ciVbir\"></div><!--/$--><!--$--><p class=\"block core-block\">\"We are incredibly excited about the strength we're seeing across our products and services, and we expect the December quarter's revenue to be the best ever for the company and the best ever for iPhone,\" Cook said.</p><!--/$--><!--$--><p class=\"block core-block\">Cook highlighted the company's lineup that includes the iPhone 17, an updated Apple Watch, AirPods Pro 3 and other new devices.</p><!--/$--><!--$--><p class=\"block core-block\">On the iPhone 17, Cook said the smartphone \"has had a tremendous response from our users around the world.\"</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Read Also: <a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/10/48564528/apple-experts-bullish-after-q4-eventual-winner-in-ai\" target=\"_blank\">Apple Experts Bullish After Q4—’Eventual Winner’ In AI</a></strong></p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">First Quarter Records Coming</h2><!--/$--><!--$--><p class=\"block core-block\">Apple Chief Financial Officer <strong>Kevin Parekh</strong> helped quantify what Cook meant when he said the first quarter could set records.</p><!--/$--><!--$--><p class=\"block core-block\">\"From today we expect our December quarter total company revenue to grow by 10% to 12% year-over-year, which would be our best quarter ever,\" Parekh said.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Apple reported revenue of $124.30 billion in<a href=\"https://www.benzinga.com/news/earnings/25/01/43355688/apple-q1-earnings-revenue-beat-eps-beat-iphone-sales-slip-installed-base-climbs-to-all-time-high-our-best-quarter-ever\" target=\"_blank\"> last year's first quarter</a>, a new company record at the time. The estimated 10% to 12% growth would make this year's first quarter revenue total $136.73 billion to $139.22 billion.</p><!--/$--><!--$--><p class=\"block core-block\">Analysts currently estimate <span style=\"box-sizing:border-box;margin:0px;padding:0px\">Apple’s first</span>-quarter revenue at $132.31 billion, according to <a href=\"https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent103125&amp;t=be2bearmibe3na1\" target=\"_blank\">Benzinga Pro.</a></p><!--/$--><!--$--><p class=\"block core-block\">Parekh said the first quarter would also be \"our best iPhone quarter ever,\" with iPhone revenue expected to grow \"double digits\" year over year.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">iPhone revenue was $69.14 billion in last year's first quarter. Based on a 10% growth rate, the total would hit $76.06 billion or more in this year's first quarter.</p><!--/$--><!--$--><p class=\"block core-block\">For comparison, Apple just reported fourth-quarter iPhone revenue of $49.02 billion.</p><!--/$--><!--$--><p class=\"block core-block\">Apple's fourth quarter results marked the 11<sup>th</sup> straight quarter the company has posted a double beat, with revenue and earnings per share both coming in ahead of analyst estimates.</p><!--/$--><!--$--><p class=\"block core-block\">Fourth-quarter results included a fourth-quarter revenue record, a fourth-quarter iPhone revenue record, and an all-time record for Services revenue.</p><!--/$--><!--$--><p class=\"block core-block\">Based on comments from Apple executives, the company's first quarter could see multiple records fall once again.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Apple Stock Hits New Highs</h2><!--/$--><!--$--><p class=\"block core-block\">Apple shares traded at $271.56 on Friday. The stock hit a new all-time high of $277.32 during Friday's trading session. Apple shares are up 11.3% year-to-date in 2025.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48571272\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/markets/tech/25/10/48551958/tim-cook-reveals-apple-set-record-for-iphone-upgraders-in-september-were-constrained-today-on-several-models\" target=\"_blank\">Tim Cook Reveals Apple Set Record For iPhone Upgraders In September: ‘We’re Constrained Today On Several Models…’</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Image created using artificial intelligence via Midjourney.</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/31/apple-mid5.png",
            "link": "https://www.benzinga.com/trading-ideas/long-ideas/25/10/48571272/apple-breaks-records-in-q4-tim-cook-says-q1-will-be-even-better-the-best-ever-for-the-company",
            "pub_date": "2025-11-01 02:53:24",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "690505b2ecb8a70001463262",
            "title": "Why Is Netflix Stock Up Today?",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">Shares of <strong>Netflix, Inc.</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/NFLX\" target=\"_blank\">NFLX</a>) are rising Friday after the company announced a significant change <a href=\"https://www.benzinga.com/wiim/25/10/48555249/netflix-shares-are-trading-higher-after-the-company-announced-a-10-for-1-forward-stock-split\" target=\"_blank\">to its stock</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>What To Know: </strong>Netflix announced a ten-for-one forward stock split of the company’s common stock. </p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Shares were up slightly above opening price and trading around $1,119 at last check, <a href=\"https://pro.benzinga.com/\" target=\"_blank\">according to Benzinga Pro</a>. </p><!--/$--><!--$--><p class=\"block core-block\">Each shareholder of record as of the close of trading on Monday, November 10, 2025 will receive, after the close of trading on Friday, November 14, 2025, nine additional shares for every share held on the record date. Trading is expected to begin on a split-adjusted basis at market open on Monday, November 17, 2025.</p><!--/$--><!--$--><p class=\"block core-block\">The company said the purpose of the stock split is to reset the market price of the Company’s common stock to a range that will be more accessible to employees who participate in the Company’s stock option program.</p><!--/$--><!--$--><div class=\"sc-fzzUx jSgJNL\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>NFLX Analysis:</strong> Netflix is trading approximately 6.6% below its 50-day moving average of $1197.31, indicating a potential resistance level that may need to be overcome for a sustained upward trend. The stock is also trading just slightly below its 200-day moving average of $1120.42, which could act as a critical support level in the near term.</p><!--/$--><!--$--><p class=\"block core-block\">The recent price action has brought Netflix to a support level of $1087.30, which aligns closely with the 200-day moving average. If the stock were to break below this level, it could signal further weakness and potentially test the lower bounds of its 52-week range. Conversely, a rally above the resistance level of $1248.59 would suggest a strong bullish reversal, allowing for a more optimistic outlook for investors.</p><!--/$--><!--$--><p class=\"block core-block\">Year-to-date, Netflix has shown impressive performance, up 26.2%, reflecting strong market sentiment and investor confidence in its growth prospects.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>NFLX Price Action: </strong>Shares were up 2.91% at $1120.52 at the time of publication on Friday. The stock is trading within its 52-week range of $747.77 to $1341.15.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48571277\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><a href=\"https://www.benzinga.com/markets/equities/25/10/48551238/marjorie-taylor-greene-buys-netflix-stock-after-downbeat-q3-earnings-expands-big-tech-bet\" target=\"_blank\"><strong>Marjorie Taylor Greene Buys Netflix Stock After Downbeat Q3 Earnings, Expands Big Tech Bet<br/></strong></a></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Image: Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/31/Netflix-Inc-.jpeg",
            "link": "https://www.benzinga.com/trading-ideas/movers/25/10/48571277/why-is-netflix-stock-up-today",
            "pub_date": "2025-11-01 02:53:41",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69050d36ecb8a700014636af",
            "title": "Why Is Twilio Stock Up Today?",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">Shares of <strong>Twilio Inc.</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/TWLO\" target=\"_blank\">TWLO</a>) are trading higher Friday after the company reported <a href=\"https://www.benzinga.com/markets/earnings/25/10/48544648/twilio-stock-surges-on-q3-earnings-beat-strong-guidance-broad-based-strength-across-customer-segments\" target=\"_blank\">third-quarter earnings.</a></p><!--/$--><!--$--><p class=\"block core-block\"><em>TWLO is surging to new heights today. <a href=\"https://www.benzinga.com/quote/TWLO\" rel=\"noreferrer noopener\" target=\"_blank\">Follow the breaking news here.</a></em></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>What To Know:</strong> Twilio reported better than expected results and issued fourth quarter guidance above analyst expectations. It brought in $1.3 billion in revenue, a new quarterly record, beating estimates of $1.25 billion. </p><!--/$--><!--$--><p class=\"block core-block\">Shares were up around 20% following the news, <a href=\"https://pro.benzinga.com/dashboard\" target=\"_blank\">according to Benzinga Pro</a>. </p><!--/$--><!--$--><p class=\"block core-block\">For fiscal year 2025, Twilio is raising its revenue growth range to 12.4% to 12.6%, compared with 10% to 11% previously, and its organic revenue growth range to 11.3% to 11.5% year-over-year, compared with 9% to 10% previously. <br/></p><!--/$--><!--$--><div class=\"sc-SfCGz ciVbir\"></div><!--/$--><!--$--><p class=\"block core-block\">\"We saw broad-based strength across customer segments, ranging from startups to enterprises to ISVs, that continue to choose Twilio to power their customer engagement,” said <strong>Khozema Shipchandler</strong>, CEO of Twilio. “Our team is looking to finish the year off strong by helping our customers build relationships that grow stronger and more meaningful with every engagement.\"</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Analyst Changes:</strong> Following the company's quarterly results, several analysts lifted price targets.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li>JP Morgan analyst Mark Murphy maintained an Overweight and raised the price target from $140 to $145.</li>\n<li>Piper Sandler analyst James Fish maintained an Overweight and raised the price target from $144 to $145.</li>\n<li>Keybanc analyst Jackson Ader maintains an Overweight and raised the price target from $146 to $156.</li>\n<li>Rosenblatt analyst Catharine Trebnick maintained a Buy and a $140 price target.</li>\n</ul><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>TWLO Analysis:</strong> Twilio is trading approximately 28% above its 50-day moving average of $106.63 and about 21.7% above its 200-day moving average of $112.17. This positioning indicates a strong bullish trend, suggesting that the stock has gained substantial traction in recent trading sessions. The relative strength index (RSI) sits at 57.35, signaling a neutral stance that leaves room for further upward movement without being overbought.</p><!--/$--><!--$--><p class=\"block core-block\">As the stock approaches its 52-week high of $151.94, it faces psychological resistance at this level, which could act as a barrier to further gains. The absence of calculated support levels suggests that the 50-day moving average may serve as a key support point, providing a cushion should the price experience any pullbacks.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>TWLO Price Action:</strong> Twilio shares were up 21.14% at $136.72 at the time of publication on Friday. <a href=\"https://editorial.benzinga.com/\" rel=\"noreferrer noopener\" target=\"_blank\">according to Benzinga Pro</a>.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48572311\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><a href=\"https://www.benzinga.com/analyst-stock-ratings/price-target/25/10/48555811/these-analysts-increase-their-forecasts-on-twilio-following-strong-q3-results\" target=\"_blank\"><strong>These Analysts Increase Their Forecasts On Twilio Following Strong Q3 Results</strong></a></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Image: Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/31/San-Jose--Ca--Usa---Nov-29--2023-Twilio-_1.jpeg",
            "link": "https://www.benzinga.com/trading-ideas/movers/25/10/48572311/why-is-twilio-stock-up-today",
            "pub_date": "2025-11-01 03:25:35",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69050c20ecb8a70001463624",
            "title": "Oklo Stock Is Falling Friday: What&#39;s Going On?",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Oklo Inc</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/OKLO\" target=\"_blank\">OKLO</a>) shares are trading lower Friday afternoon, continuing a volatile week driven by conflicting catalysts for the nuclear startup. Here’s what investors <a href=\"https://www.benzinga.com/trading-ideas/movers/25/10/48467803/nuclear-stocks-boom-on-camecos-deal-with-trump-administration\" target=\"_blank\">need to know</a>.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li>OKLO is having a challenging session. <a href=\"https://www.benzinga.com/quote/OKLO\" rel=\"noreferrer noopener\" target=\"_blank\">Check the full analysis here.</a></li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>What To Know:</strong> The stock surged early in the week on sector-wide optimism after news of an $80 billion deal between <strong>Cameco</strong> and the Trump administration to construct new reactors. However, the rally faded as investors re-evaluated Oklo’s “<a href=\"https://www.benzinga.com/trading-ideas/movers/25/10/48440402/oklo-stock-is-falling-today-whats-going-on\" target=\"_blank\">fundamental risks</a>,” including its pre-revenue status.</p><!--/$--><!--$--><p class=\"block core-block\">Adding to the week’s news, Oklo filed a Form S-3 shelf registration with the SEC on Wednesday. This filing allows the company to offer and sell up to <a href=\"https://d18rn0p25nwr6d.cloudfront.net/CIK-0001849056/82d9bb33-7834-463a-9fd4-fe5a6ff09308.pdf\" target=\"_blank\">$3.5 billion</a> in aggregate of various securities, including common stock, preferred stock and debt securities. The registration could provide future financing flexibility, permitting Oklo to sell these securities from time to time.</p><!--/$--><!--$--><p class=\"block core-block\">Analyst ratings have been mixed, with <a href=\"https://www.benzinga.com/quote/OKLO/analyst-ratings\" target=\"_blank\">recent downgrades</a> from B of A Securities and Seaport Global, but new Buy or Overweight initiations from Canaccord Genuity and Barclays. Investors are now looking toward Oklo’s quarterly <a href=\"https://www.benzinga.com/quote/OKLO/earnings\" target=\"_blank\">earnings report</a> on Nov. 11. Analysts are forecasting a loss of 13 cents per share.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Benzinga Edge Rankings:</strong> Reflecting its recent volatility, <a href=\"http://benzinga.grsm.io/register174\" target=\"_blank\">Benzinga Edge</a> stock rankings show OKLO with a high Momentum score of 99.29.</p><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\"><strong>OKLO Price Action:</strong> Oklo shares were down 2.5% at $133.94 at the time of publication on Friday, <a href=\"https://www.benzinga.com/pro/\" rel=\"noreferrer noopener\" target=\"_blank\">according to Benzinga Pro data</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Read Also: <a href=\"https://www.benzinga.com/trading-ideas/movers/25/10/48567021/reddit-shares-are-trading-higher-friday-whats-going-on\" target=\"_blank\">Reddit Shares Are Trading Higher Friday: What’s Going On?</a></strong></p><!--/$--><!--$--><div class=\"sc-gQfuga iaHpuj\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">How To Buy OKLO Stock</h2><!--/$--><!--$--><p class=\"block core-block\">Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p><!--/$--><!--$--><p class=\"block core-block\">For example, in Oklo’s case, it is in the Utilities sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Image: Shutterstock</em></p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48572186\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/31/Oklo-Inc-.jpeg",
            "link": "https://www.benzinga.com/trading-ideas/movers/25/10/48572186/oklo-stock-is-falling-friday-whats-going-on",
            "pub_date": "2025-11-01 03:21:08",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "690507f0ecb8a70001463386",
            "title": "A Glimpse of Castle Biosciences&#39;s Earnings Potential",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">Castle Biosciences (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CSTL\" target=\"_blank\">CSTL</a>) will release its quarterly earnings report on Monday, 2025-11-03. Here's a brief overview for investors ahead of the announcement.</p><!--/$--><!--$--><p class=\"block core-block\">Analysts anticipate Castle Biosciences to report an <strong>earnings per share</strong> (EPS) of $-0.44.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The announcement from Castle Biosciences is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p><!--/$--><!--$--><p class=\"block core-block\">It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p><!--/$--><!--$--><h3 class=\"block core-block\">Past Earnings Performance</h3><!--/$--><!--$--><p class=\"block core-block\">During the last quarter, the company reported an EPS beat by $0.65, leading to a 32.83% increase in the share price on the subsequent day.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a look at Castle Biosciences's past performance and the resulting price change:</p><!--/$--><!--$--><div class=\"sc-eQzVdq kfhAgV\"></div><!--/$--><!--$--><!--/$--><!--$--><div class=\"sc-feVKPA LhjAx core-image flex items-center justify-center\"><span style=\"background:none;border:0;box-sizing:border-box;display:inline-block;height:initial;margin:0;opacity:1;overflow:hidden;padding:0;width:initial;position:relative;max-width:100%\"><span style=\"background:none;border:0;box-sizing:border-box;display:block;height:initial;margin:0;opacity:1;padding:0;width:initial;max-width:100%\"><img alt=\"\" aria-hidden=\"true\" src=\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iNzAwIiBoZWlnaHQ9IjUwMCIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIiB2ZXJzaW9uPSIxLjEiLz4=\" style=\"background:none;border:0;display:block;height:initial;margin:0;max-width:100%;opacity:1;padding:0;width:initial\"/></span><img alt=\"\" decoding=\"async\" loading=\"lazy\" src=\"data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/><noscript><img alt=\"\" decoding=\"async\" fetchpriority=\"low\" loading=\"lazy\" sizes=\"(max-width: 800px) 700px, (min-width: 800px) 700px\" src=\"https://www.benzinga.com/files/images/story/2025/1761937392_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=1920\" srcset=\"https://www.benzinga.com/files/images/story/2025/1761937392_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=750 1x, https://www.benzinga.com/files/images/story/2025/1761937392_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=1920 2x\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/></noscript></span></div><!--/$--><!--$--><h3 class=\"block core-block\">Stock Performance</h3><!--/$--><!--$--><p class=\"block core-block\">Shares of Castle Biosciences were trading at $24.21 as of October 30. Over the last 52-week period, shares are down 25.98%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Analyst Views on Castle Biosciences</h3><!--/$--><!--$--><p class=\"block core-block\">Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Castle Biosciences.</p><!--/$--><!--$--><p class=\"block core-block\">Castle Biosciences has received a total of 1 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $37.0, the consensus suggests a potential 52.83% upside.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Peer Ratings Comparison</h3><!--/$--><!--$--><p class=\"block core-block\">The below comparison of the analyst ratings and average 1-year price targets of Fulgent Genetics, AMN Healthcare Services and InnovAge Holding, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p><!--/$--><!--$--><ul class=\"block core-block\">\n<li>Analysts currently favor an Buy trajectory for Fulgent Genetics, with an average 1-year price target of $25.5, suggesting a potential 5.33% upside.</li>\n<li>Analysts currently favor an Outperform trajectory for AMN Healthcare Services, with an average 1-year price target of $21.5, suggesting a potential 11.19% downside.</li>\n<li>Analysts currently favor an Underperform trajectory for InnovAge Holding, with an average 1-year price target of $5.0, suggesting a potential 79.35% downside.</li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Comprehensive Peer Analysis Summary</h3><!--/$--><!--$--><p class=\"block core-block\">The peer analysis summary outlines pivotal metrics for Fulgent Genetics, AMN Healthcare Services and InnovAge Holding, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\">Key Takeaway:</p><!--/$--><!--$--><p class=\"block core-block\">Castle Biosciences ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p><!--/$--><!--$--><h3 class=\"block core-block\">Discovering Castle Biosciences: A Closer Look</h3><!--/$--><!--$--><p class=\"block core-block\">Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.</p><!--/$--><!--$--><h3 class=\"block core-block\">Castle Biosciences: Financial Performance Dissected</h3><!--/$--><!--$--><p class=\"block core-block\"><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Negative Revenue Trend:</strong> Examining Castle Biosciences's financials over 3 months reveals challenges. As of 30 June, 2025, the company experienced a decline of approximately <strong>-0.94%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>5.25%,</strong> the company showcases strong profitability and effective cost control.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Equity (ROE):</strong> Castle Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.01%</strong> ROE, the company effectively utilizes shareholder equity capital.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Assets (ROA):</strong> Castle Biosciences's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.86%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Debt Management:</strong> Castle Biosciences's debt-to-equity ratio is below the industry average. With a ratio of <b>0.08</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p><!--/$--><!--$--><p class=\"block core-block\"><a href=\"https://www.benzinga.com/quote/CSTL/earnings\" target=\"_blank\"><strong>To track all earnings releases for Castle Biosciences visit their earnings calendar on our site.</strong></a></p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/earnings/25/10/48571556/a-glimpse-of-castle-biosciencess-earnings-potential",
            "pub_date": "2025-11-01 03:03:15",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}